Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
Identifieur interne : 000315 ( PubMed/Curation ); précédent : 000314; suivant : 000316Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
Auteurs : Camille Roubille [Canada] ; Boulos Haraoui [Canada]Source :
- Seminars in arthritis and rheumatism [ 1532-866X ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Antirhumatismaux, Facteurs biologiques.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Antirhumatismaux, Facteurs biologiques.
- Humains, Pneumopathies interstitielles.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antirheumatic Agents, Biological Factors.
- chemical , therapeutic use : Antirheumatic Agents, Biological Factors.
- chemically induced : Lung Diseases, Interstitial.
- drug therapy : Arthritis, Rheumatoid.
- Humans.
Abstract
To review published cases of induced or exacerbated interstitial lung disease (ILD) in rheumatoid arthritis (RA) associated with non-biologic disease-modifying antirheumatic drugs (nbDMARDs) and biologics and to discuss clinical implications in daily practice.
DOI: 10.1016/j.semarthrit.2013.09.005
PubMed: 24231065
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000315
Links to Exploration step
pubmed:24231065Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.</title><author><name sortKey="Roubille, Camille" sort="Roubille, Camille" uniqKey="Roubille C" first="Camille" last="Roubille">Camille Roubille</name><affiliation wicri:level="1"><nlm:affiliation>Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec</wicri:regionArea></affiliation></author><author><name sortKey="Haraoui, Boulos" sort="Haraoui, Boulos" uniqKey="Haraoui B" first="Boulos" last="Haraoui">Boulos Haraoui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada; Institut de rhumatologie de Montréal, 1551 Ontario St East, Montreal, Quebec, Canada H2L 1S6. Electronic address: boulos.haraoui@ssss.gouv.qc.ca.</nlm:affiliation><country>Canada</country><wicri:regionArea>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada; Institut de rhumatologie de Montréal, 1551 Ontario St East, Montreal, Quebec</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24231065</idno><idno type="pmid">24231065</idno><idno type="doi">10.1016/j.semarthrit.2013.09.005</idno><idno type="wicri:Area/PubMed/Corpus">000315</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000315</idno><idno type="wicri:Area/PubMed/Curation">000315</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000315</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.</title><author><name sortKey="Roubille, Camille" sort="Roubille, Camille" uniqKey="Roubille C" first="Camille" last="Roubille">Camille Roubille</name><affiliation wicri:level="1"><nlm:affiliation>Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec</wicri:regionArea></affiliation></author><author><name sortKey="Haraoui, Boulos" sort="Haraoui, Boulos" uniqKey="Haraoui B" first="Boulos" last="Haraoui">Boulos Haraoui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada; Institut de rhumatologie de Montréal, 1551 Ontario St East, Montreal, Quebec, Canada H2L 1S6. Electronic address: boulos.haraoui@ssss.gouv.qc.ca.</nlm:affiliation><country>Canada</country><wicri:regionArea>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada; Institut de rhumatologie de Montréal, 1551 Ontario St East, Montreal, Quebec</wicri:regionArea></affiliation></author></analytic><series><title level="j">Seminars in arthritis and rheumatism</title><idno type="eISSN">1532-866X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (adverse effects)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Biological Factors (adverse effects)</term><term>Biological Factors (therapeutic use)</term><term>Humans</term><term>Lung Diseases, Interstitial (chemically induced)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antirhumatismaux (effets indésirables)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Facteurs biologiques (effets indésirables)</term><term>Facteurs biologiques (usage thérapeutique)</term><term>Humains</term><term>Pneumopathies interstitielles ()</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antirheumatic Agents</term><term>Biological Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Biological Factors</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antirhumatismaux</term><term>Facteurs biologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term><term>Facteurs biologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pneumopathies interstitielles</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To review published cases of induced or exacerbated interstitial lung disease (ILD) in rheumatoid arthritis (RA) associated with non-biologic disease-modifying antirheumatic drugs (nbDMARDs) and biologics and to discuss clinical implications in daily practice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24231065</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-866X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Seminars in arthritis and rheumatism</Title><ISOAbbreviation>Semin. Arthritis Rheum.</ISOAbbreviation></Journal><ArticleTitle>Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.</ArticleTitle><Pagination><MedlinePgn>613-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semarthrit.2013.09.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-0172(13)00201-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review published cases of induced or exacerbated interstitial lung disease (ILD) in rheumatoid arthritis (RA) associated with non-biologic disease-modifying antirheumatic drugs (nbDMARDs) and biologics and to discuss clinical implications in daily practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a systematic literature review from 1975 to July 2013 using Medline, Embase, Cochrane, and abstracts from the ACR 2010-2012 and EULAR 2010-2013 annual meetings. Case reports and series that suggest a causative role of nbDMARDs (methotrexate [MTX], leflunomide [LEF], gold, azathioprine [AZA], sulfasalazine [SSZ], and hydroxychloroquine [HCQ]) and biologic agents (TNF inhibitors [TNFi], rituximab [RTX], tocilizumab [TCZ], abatacept [ABA], and anakinra) in causing ILD or worsening a pre-existing ILD in RA patients were included. Results from observational and postmarketing studies as well as reviews on this topic were excluded from the qualitative analysis but still considered to discuss the implication of such drugs in generating or worsening ILD in RA patients. Comparisons were made between MTX-induced ILD in RA and the cases reported with other agents, in terms of clinical presentation, radiological features, and therapeutic management and outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The literature search identified 32 articles for MTX, 12 for LEF (resulting in 34 case reports), 3 for gold, 1 for AZA, 4 for SSZ, 27 for TNFi (resulting in 31 case reports), 3 for RTX, 5 for TCZ (resulting in 8 case reports), and 1 for ABA. No case was found for HCQ or anakinra. Common points are noted between LEF- and TNFi-related ILD in RA: ILD is a rare severe adverse event, mostly occurs within the first 20 weeks after initiation of therapy, causes dyspnea mostly in older patients, and can be fatal. Although no definitive causative relationship can be drawn from case reports and observational studies, these data argue for a pulmonary follow-up in RA patients with pre-existing ILD, while receiving biologic therapy or nbDMARDs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As previously described for MTX, growing evidence highlights that LEF, TNFi, RTX, and TCZ may induce pneumonitis or worsen RA-related pre-existing ILD. Nonetheless, identifying a causal relationship between RA therapy and ILD-induced toxicity clearly appears difficult, partly because it is a rare condition.</AbstractText><CopyrightInformation>© 2013 Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roubille</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haraoui</LastName><ForeName>Boulos</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada; Institut de rhumatologie de Montréal, 1551 Ontario St East, Montreal, Quebec, Canada H2L 1S6. Electronic address: boulos.haraoui@ssss.gouv.qc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Arthritis Rheum</MedlineTA><NlmUniqueID>1306053</NlmUniqueID><ISSNLinking>0049-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001685">Biological Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001685" MajorTopicYN="N">Biological Factors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Interstitial lung disease</Keyword><Keyword MajorTopicYN="N">Leflunomide</Keyword><Keyword MajorTopicYN="N">Methotrexate</Keyword><Keyword MajorTopicYN="N">Pneumonitis</Keyword><Keyword MajorTopicYN="N">Pulmonary fibrosis</Keyword><Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">Rituximab</Keyword><Keyword MajorTopicYN="N">TNF inhibitors</Keyword><Keyword MajorTopicYN="N">Tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>09</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24231065</ArticleId><ArticleId IdType="pii">S0049-0172(13)00201-1</ArticleId><ArticleId IdType="doi">10.1016/j.semarthrit.2013.09.005</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000315 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000315 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24231065
|texte= Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24231065" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |